A Bullish Call for Pfizer: Analysts Spot a Turning Point

Pfizer finds itself at the center of investor attention this Friday, driven by two concurrent events. Beyond the routine distribution of its quarterly dividend, a fresh analyst upgrade is injecting a dose of optimism into the pharmaceutical giant’s narrative. As revenue from its Covid-related portfolio continues to decline, market hopes are increasingly pinned on tangible progress within its drug development pipeline, which could potentially lead to a corporate re-rating.

A Strategic Upgrade Breaks from the Pack

The most significant market move this week originated from Argus Research. The firm’s analysts have shifted their stance, upgrading Pfizer from a “Hold” to a “Buy” rating and attaching a price target of $35.00. This move is particularly notable for its divergence from the broader consensus. A majority of market watchers remain in a cautious, wait-and-see mode, with the average price target currently standing at just over $28. The upgrade signals that some segments of the market are starting to look beyond the company’s present structural challenges.

Financial Resilience and Upcoming Hurdles

Adding to the day’s developments, Pfizer is distributing its first-quarter dividend—marking an unbroken streak of 349 consecutive quarterly payments. This consistency highlights the firm’s underlying financial strength, even as its outlook presents a mixed picture. Management anticipates a further decline in revenue from Covid products of approximately $1.5 billion for the full year 2026. This is compounded by patent expirations expected to cause revenue losses of a similar magnitude. Despite these headwinds, the share price has stabilized since the start of the year, currently showing a gain of 6.68 percent.

Should investors sell immediately? Or is it worth buying Pfizer?

Trading at a price-to-earnings (P/E) ratio below 10, compared to an industry average nearing 19, the stock appears fundamentally undervalued. The critical factor for future performance will now be the operational execution of the 20 Phase 3 trials announced for this year, which are tasked with offsetting the fading Covid-related sales.

Pipeline Progress Fuels Long-Term Optimism

The improved sentiment is largely rooted in Pfizer’s strategic pivot toward the weight-loss market. The company reported positive data from a Phase 2b study for its GLP-1 candidate, PF’3944. Its potential competitive edge against established leaders Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) lies in dosing frequency: the Pfizer drug candidate requires only a once-monthly injection versus the current standard of weekly doses. This patient convenience factor could secure vital market share once the planned Phase 3 trials commence in 2026.

Progress is also evident in Pfizer’s oncology segment. The U.S. Food and Drug Administration (FDA) recently accepted for priority review a supplemental application for an expanded indication of the hemophilia therapy, HYMPAVZI.